At Vitrolife’s Annual General Meeting yesterday, April 29, the following, amongst other things, was decided:
April 30, 2013
Gothenburg, Sweden
VITROLIFE AB (publ)
The Board
Queries should be addressed to:
Carsten Browall, Chairman of the Board, phone 46 70 255 65 32
Mikael Engblom, CFO, phone 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 30, at 8.30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
_________________________________________________________________________________________________________________
Vitrolife is a global medical device Group. Vitrolife Fertility product area develops, produces and markets products for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 230 employees and the company's products are sold in approximately 100 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/